XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3Close
Consolidated Statements of Earnings - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues:        
Net earned premiums, principally supplemental health insurance [1] $ 3,328 $ 3,476 $ 10,109 $ 10,737
Net investment income 1,006 1,004 3,100 2,946
Net investment gains (losses) (1,408) 423 239 1,101
Other income (loss) 23 47 76 139
Total revenues 2,949 4,950 13,524 14,923 Close
Benefits and expenses:        
Benefits and claims, excluding reserve remeasurement 2,003 2,065 6,042 6,420
Reserve remeasurement (gains) losses (408) (205) (515) (312)
Total benefits and claims, net 1,595 1,860 5,527 6,108
Acquisition and operating expenses:        
Amortization of deferred policy acquisition costs 214 201 638 608
Insurance commissions 251 250 751 797
Insurance and other expenses 747 785 2,179 2,290
Interest expense 50 49 147 148
Total acquisition and operating expenses 1,262 1,285 3,715 3,843
Total benefits and expenses 2,857 3,145 9,242 9,951 Close
Earnings before income taxes 92 1,805 4,282 4,972 Close
Income taxes 185 236 741 581 Close
Net earnings $ (93) $ 1,569 $ 3,541 $ 4,391 Close
Net earnings per share:        
Basic (in dollars per share) $ (0.17) $ 2.65 $ 6.26 $ 7.31
Diluted (in dollars per share) $ (0.17) $ 2.64 $ 6.23 $ 7.28
Weighted-average outstanding common shares used in computing earnings per share (In thousands):        
Basic (in shares) 557,899 591,246 565,757 600,991
Diluted (in shares) 560,414 593,596 568,216 603,419
Cash dividends per share $ 0.50 $ 0.42 $ 1.50 $ 1.26
[1] Includes a gain (loss) of $(75) and $22 for the three-month periods and $(80) and $22 for the nine-month periods ended September 30, 2024 and 2023, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.